Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 5Recruiting 4Terminated 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 6Lung Neoplasms 6Prostatic Neoplasms 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Osteosarcoma 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Barrett Esophagus 3Urinary Bladder Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Biphenotypic, Acute 2Gastroesophageal Reflux 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1

Interventions

Cyclophosphamide 32Tacrolimus 29fludarabine 27Mycophenolic Acid 23fludarabine phosphate 22Busulfan 19Whole-Body Irradiation 18Melphalan 16Methotrexate 15Antilymphocyte Serum 14Rituximab 12Bortezomib 11Stem Cell Transplantation 10Cyclosporine 10thymoglobulin 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Interviews as Topic 7Filgrastim 7Dexamethasone 7Clofarabine 7Blood Specimen Collection 6Alemtuzumab 6merphos 5Voriconazole 5Standard of Care 5Nivolumab 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hematologic Neoplasms × Specimen Handling × Clear all
NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled 16 charts
DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡